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In hepatic microsomes one or more isozymes of cytochrome P-450 inhibits the ATP-dependent Ca*+ pump. This inhibition is reversible by GSH 
and appears to be due to a direct oxidation of the pump proteins by the oxygenated cytochrome. To determine which isozyme mediates this inhibiton, 
we have examined the effect of various substrates and inhibitors on the NADPH inhibition of Ca*+ uptake. We find that aminopyrine, benzpheta- 
mine and SKF-525A reverse this inhibition while a number of other substrates do not. This pattern suggests that a previously unreported isozyme 
of cytochrome P-450 mediates the Ca2+ pump inhibition. 
Cytochrome P-450 inhibition; Microsomal Ca*’ pump 
1. INTRODUCTION [9] have been the most widely employed agents in these 
studies. 
NADPH inhibits the ATP-dependent Ca2+ pump of 
hepatic microsomes from untreated male rats by 
20-50% [l-3]. This inhibition is blocked by nitrogen 
and partially by CO/Oz, suggesting that it is mediated 
through a cytochrome P-450 pathway. Further, it is 
reserved by GSH through a reparative process [l-3]. 
Since it is known that the sulfhydryls of the Ca2+ pump 
are readily oxidized with a loss of Ca2+ uptake [4], these 
data suggest hat NADPH serves as a cofactor for the 
cytochrome P-450 catalyzed production of reactive 
oxygen which reversibly oxidizes the pump [l-3]. The 
reactive oxygen is not released into the medium, since 
reactive oxygen scavengers have no effect on the inhibi- 
tion [3]. Hence a cytochrome P-450-feroxyl species is 
apparently in close proximity to the pump and directly 
oxidizes it [2]. 
Since cytochrome P-450 is a family of isoforms [5], 
the question arises as to whether all or only a few 
isozymes oxidize the Ca2+ pump. To assess the role of 
the various forms in this inhibition, we have examined 
the effect of a number of substrates and inhibitors on 
the NADPH effect. Since various agents show marked 
differences in metabolism with different forms of 
cytochrome P-450, this approach has proven to be a 
powerful technique, both in vivo and in vitro, to deter- 
mine which cytochrome P-450 isoform catalyzes a 
hydroxylation reaction. Testosterone [8] and warfarin 
In the current study we have utilized this technique to 
determine which cytochrome P-450 isoform(s) catalyzes 
the NADPH inhibition of the Ca2+ pump by examining 
whether various substrates for and inhibitors of the 
cytochrome P-450-dependent mixed-function oxidases 
block the NADPH inhibition of Ca2+ uptake. These 
studies are based on the assumption that if a substrate 
is metabolized by the cytochrome P-450 isoform which 
also mediates the NADPH inhibition, then the addition 
of the substrate should compete for the activated ox- 
ygen and reverse the NADPH inhibition of the pump. 
Although there are exceptions to this concept, it is prob- 
ably generally valid. A similar result should be seen if 
an inhibitor is added to the incubations, whether it acts 
as a competitive substrate for the oxygenated cyto- 
chrome or by blocking the formation of the oxygenated 
cytochrome P-450. We have not used either testoste- 
rone or warfarin in these studies since they are both 
metabolized by a large number of isozymes and would 
therefore not delineate which form inhibits the pump. 
We have, instead, examined the effect of substrates 
with only one or two major metabolic reactions. We 
find that the NADPH inhibition of the Ca2+ pump ap- 
pears to be catalyzed by a cytochrome P-450 isoform(s) 
which catalyzes the metabolism of aminopyrine and 
benzphetamine, is inhibited by SKF-525A and im- 
idazole, and is stimulated by metyrapone. 
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2. MATERIALS AND METHODS 
Glucose 6-phosphate, NADP+, ATP, and glucose 6-phosphate 
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dehydrogenase were obtained from Sigma Chemical Co. (St. Louis, 
MO); aminopyrine from J.T. Baker (Phillipsburg, NJ); ethylmor- 
phine from Merck (Rahway, NJ); hexobarbital from Winthrop 
Laboratories (New York, NY); aniline and 7-ethoxycoumarin from 
Aldrich Chemical Co. (Milwaukee, WI); and 45CaC1z (NEZ-013) 
from New England Nuclear (Boston, MA). Benzphetamine was a gift 
of UpJohn Laboratories (Kalamazoo, MI); zoxazolamine of NcNeil 
Laboratories (Fort Washington, PA); and SKF-52.5A of Smith Kline 
Laboratories (Philadelphia, PA). 
Microsomes were prepared from male, Sprague-Dawley rats 
(140-160 g) and Ca’+ uptake was determined as previously described 
[2]. incubations were run in triplicate with drug concentrations from 
10 pM to 2 mM in the presence of 1 mM NADP+ or NADPH. The 
coefficient of variation was 5% for both the basal Ca*+ uptakes and 
the percentages of the NADPH inhibition for incubations performed 
on a single preparation. All studies were replicated 3 or more times 
and gave the same pattern on replication. Protein was determined by 
the method of Lowry et al. [S]. 
3. RESULTS AND DISCUSSION 
Benzphetamine (750 PM) completely blocked the 
NADPH inhibition of Ca2+ uptake (Fig. 1). SKF-525A 
(5 PM) and imidazole (100 PM) showed similar patterns 
(Table I). Aminopyrine only partially blocked the 
NADPH inhibition with a half-maximal effect at 750 
PM. On the basis of the reported metabolic activities of 
the rat cytochromes P-450 isoforms, these data indicate 
that cytochromes P-450a [9,10], P-450f [ll], P-450g 
[ 111, P-450pcnl [12], P-450 RLM 5b [13] and P-450 
LAW [14] could not mediate the NADPH inhibition of 
the Ca2+ pump, since they do not metabolize either 
aminopyrine or benzphetamine. 
Metyrapone, an inhibitor of only some isoforms of 
cytochrome P-450, had no effect on the NADPH in- 
hibition of the Ca’+ pump in concentrations up to 500 
PM, but at l-2 mM it increased the NADPH inhibition 
to 53% compared to an inhibition of 36070 seen in the 
absence of metyrapone (Table I). Hence cytochromes 
P-450b and P-450e are not likely candidates, even 
though they both actively metabolize benzphetamine 
[lo], since both are also inhibited by metyrapone [151. 
Further, cytochrome P-450b metabolizes hexobarbital, 
which had no effect (Table I). Even though cyto- 
chrome PB-1 is stimulated by metyrapone 1151, it also 
-104. I : : : / : : 










Fig. 1. The percentage of NADPH inhibition of the Ca” uptake at [l] Prasad, J.S., Erickson, R.R., Crankshaw, D.L. and Hohzman, 
each concentration of benzphetamine. J.L. (1986) Arch. Biochem. Biophys. 248, 639-645. 
Table I 
The effect of substrates and inhibitors of the cytochrome P-450 
dependent mixed-function oxidases on the NADPH induced inhibi- 
tion of the hepatic ATP-dependent, microsomal Ca*+ pump 
Block inhibition Increase 
inhibition 












a The effect of all substrates was determined at 10 /M-2 mM in the 
presence of NADP+ and NADPH. The NADPH inhibition was 
taken as blocked if at 1 mM the substrate or inhibitor showed more 
than 50% reversal of the NADPH inhibition when compared to the 
Ca2+ uptake seen with NADP+ at the same concentration of 
substrate. Incubations at all concentrations of drug or inhibitor 
were run in triplicate 
has a high turnover number for p-nitroanisole [lOj 
which had no effect here and therefore this isoform 
does not appear to catalyze the NADPH inhibition 
(Table I). 
Aniline, ethylmorphine, 7-ethoxycoumarin, hexobar- 
bital, morphine, p-nitroanisole and zoxazolamine had 
no effect on Ca2+ uptake in the presence of either 
NADP+ or NADPH (Table I). Hence cytochromes 
P-450~ or P-450d are not involved, since both readily 
metabolize 7-ethoxycoumarin and zoxazolamine [9]. 
Similarly cytochromes P-450h and C-M/F are not in- 
volved since they actively metabolize ethylmorphine 
[ 10, 1 1,161. Further, cytochrome P-450j probably does 
not catalyze this inhibition since it readily metabolizes 
aniline [17]. Cytochrome P-450 dbl is probably not in- 
volved since it 0-dealkylates codeine and should 
therefore have been blocked by ethylmorphine [181. 
In conclusion, these studies indicate that only a 
limited number of forms of cytochrome P-450 modu- 
late the activity of the hepatic microsomal Ca2+ pump 
and suggest hat none of the forms which have been 
purified to date catalyze this inhibition. Our current 
studies do suggest hat immunoinhibition studies with 
antibodies to some of the purified forms might assist in 
further defining which gene family is involved. In par- 
ticular, members of the CYPIIB or CIPIIIA families 
may play a role in this process, since the purified 
CYPIIB and microsomes from pregnenolone- 1&-car- 
bonitrile very actively metabolize benzphetamine, the 
most potent blocker of the substrates examined [10,121. 
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